DNMT3A and cyclic hematopoiesis: Since CHEK2 germline mutation carriers are at a higher risk of developing CH (82–84), the entire HSC pool may undergo accelerated acquisition of additional mutations, such as CHEK2 biallelic or DNMT3A mutations, that drive transformation.